Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review)
International Journal of Oncology · 06.02.2025 · 66 (3)
DOI: 10.3892/ijo.2025.5724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 06.02.2025. Verfasst von Xuebin Wan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Bladder cancer (BCa) is a prevalent malignant neoplasm of the urinary tract with high incidence rate, frequent recurrence and rapid disease progression. Conventional approaches for diagnosing, prognosticating and monitoring BCa often rely on invasive procedures such as cystoscopy and tissue biopsy, which are associated with high costs and low patient compliance for follow‑up. Liquid biopsies have advantages, such as being non‑invasive, real‑time, and reproducible, in obtaining diverse biomarkers derived from cellular, molecular, proteomic and genetic signatures in urine or plasma samples. Although plasma‑based biomarkers have been clinically validated, urine provides greater specificity for directly assessing biological materials from urological sources. The present review summarizes advancements and current limitations in urinary protein, genetic and epigenetic biomarkers for disease progression and treatment response of BC, compares performance and application scenarios of urine and blood biomarkers and explores how urinary biomarkers may serve as an alternative or complementary tool to traditional diagnostic methods. The integration of urine‑based or plasma‑based biomarkers into existing diagnostic workflows offers promising avenues for improving accuracy and efficiency of diagnosis in the management of BCa. Notably, the emergence of synthetic biomarkers and urine metabolites, combined with artificial intelligence or bioinformatic technologies, has promise in the screening of potential targets. Continued research and validation efforts are needed to translate these findings into routine clinical practice, ultimately improving patient outcomes and decreasing the burden of BCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, P.R. China.
- Department of Molecular Microbiology and Genetics, Institute for Microbiology and Genetics, University of Goettingen, Göttingen D‑37077, Germany.
- Department of Research and Development, HaploX Biotechnology, Co., Ltd., Shenzhen, Guangdong 518057, P.R. China.
- Department of Pediatrics, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China.
Zitieren
APA
Wan, X., Wang, D., Zhang, X., Xu, M., Huang, Y., Qin, W., & Chen, S. (2025). Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review). International Journal of Oncology, 66(3). https://doi.org/10.3892/ijo.2025.5724
Vancouver
Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W, et al. Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review). International Journal of Oncology. 2025;66(3). doi:10.3892/ijo.2025.5724
BibTeX
@article{Wan2025,
author = {Wan, Xuebin and Wang, Dan and Zhang, Xiaoni and Xu, Mingyan and Huang, Yuying and Qin, Wenjian and Chen, Shifu},
title = {Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review)},
journal = {International Journal of Oncology},
year = {2025},
volume = {66},
number = {3},
doi = {10.3892/ijo.2025.5724}
}
EUVIMED